Glioma genetic profiles associated with electrophysiologic hyperexcitability. medRxiv. 2023 Feb 24.
View in:
PubMed
ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Clin Cancer Res. 2023 Feb 13.
View in:
PubMed
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc Natl Acad Sci U S A. 2023 02 07; 120(6):e2219199120.
View in:
PubMed
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma. Rare Tumors. 2023; 15:20363613231152333.
View in:
PubMed
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25.
View in:
PubMed
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023 01 05; 25(1):123-134.
View in:
PubMed
Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Sci Transl Med. 2023 01 04; 15(677):eabo4778.
View in:
PubMed
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 Mar 01; 41(7):1453-1465.
View in:
PubMed
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study. Neuro Oncol. 2022 Dec 01.
View in:
PubMed
Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro Oncol. 2022 Nov 19.
View in:
PubMed
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022 11 02; 24(11):1935-1949.
View in:
PubMed
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. Curr Opin Neurol. 2022 12 01; 35(6):803-813.
View in:
PubMed
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022 10 11; 55(10):1940-1952.e5.
View in:
PubMed
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol. 2022 10 03; 24(10):1613-1646.
View in:
PubMed
A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac123.
View in:
PubMed
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open. 2022 10; 7(5):100562.
View in:
PubMed
Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2204078119.
View in:
PubMed
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 2022 08; 10(8).
View in:
PubMed
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2022 07 01; 24(7):1140-1149.
View in:
PubMed
The current state of glioma data registries. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac099.
View in:
PubMed
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clin Cancer Res. 2022 06 13; 28(12):2567-2578.
View in:
PubMed
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. Neuro Oncol. 2022 06 01; 24(6):951-963.
View in:
PubMed
A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808.
View in:
PubMed
Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. AJNR Am J Neuroradiol. 2022 05; 43(5):675-681.
View in:
PubMed
Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. Onco Targets Ther. 2022; 15:367-380.
View in:
PubMed
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac025.
View in:
PubMed
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593.
View in:
PubMed
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clin Cancer Res. 2022 02 15; 28(4):594-602.
View in:
PubMed
Is There a Role for Immunotherapy in Central Nervous System Cancers? Hematol Oncol Clin North Am. 2022 02; 36(1):237-252.
View in:
PubMed
Hematol Oncol Clin North Am. 2022 02; 36(1):xv-xvi.
View in:
PubMed
Clinical Trial Enrollment Among Adolescent and Young Adults with Primary Central Nervous System Tumors Treated at the Dana-Farber Cancer Institute. J Adolesc Young Adult Oncol. 2022 12; 11(6):543-549.
View in:
PubMed
Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. Neurooncol Pract. 2022 May; 9(3):201-207.
View in:
PubMed
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
View in:
PubMed
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 12; 22(12):1692-1704.
View in:
PubMed
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 11 02; 23(11):1961-1973.
View in:
PubMed
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. Clin Cancer Res. 2022 01 01; 28(1):129-136.
View in:
PubMed
Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat Rev Cancer. 2021 12; 21(12):786-802.
View in:
PubMed
Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab125.
View in:
PubMed
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro Oncol. 2021 08 02; 23(8):1261-1272.
View in:
PubMed
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
View in:
PubMed
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021 07; 9(7).
View in:
PubMed
A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. Front Oncol. 2021; 11:679331.
View in:
PubMed
Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma. Med (N Y). 2021 05 14; 2(5):450-452.
View in:
PubMed
Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. Acta Neurochir (Wien). 2021 07; 163(7):1883-1894.
View in:
PubMed
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-ß and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab058.
View in:
PubMed
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 2021 04 07; 11(1):7632.
View in:
PubMed
The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. Neurosurg Clin N Am. 2021 Apr; 32(2):235-248.
View in:
PubMed
IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 07; 34(7):1236-1244.
View in:
PubMed
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
View in:
PubMed
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 May; 152(3):515-522.
View in:
PubMed
Adolescent and young adult neuro-oncology: a comprehensive review. Neurooncol Pract. 2021 Jun; 8(3):236-246.
View in:
PubMed
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
View in:
PubMed
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci Rep. 2021 01 27; 11(1):2306.
View in:
PubMed
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021 05 15; 127(10):1620-1629.
View in:
PubMed
Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol. 2020 12 01; 6(12):1972-1974.
View in:
PubMed
Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply. JAMA Oncol. 2020 12 01; 6(12):1978-1979.
View in:
PubMed
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro Oncol. 2020 11 26; 22(11):1568-1579.
View in:
PubMed
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287.
View in:
PubMed
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
View in:
PubMed
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438.
View in:
PubMed
Adult immuno-oncology: using past failures to inform the future. Neuro Oncol. 2020 09 29; 22(9):1249-1261.
View in:
PubMed
Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis. Clin Transplant. 2020 11; 34(11):e14067.
View in:
PubMed
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
View in:
PubMed
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 07 01; 6(7):1003-1010.
View in:
PubMed
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? Clin Cancer Res. 2020 10 15; 26(20):5287-5296.
View in:
PubMed
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
View in:
PubMed
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
View in:
PubMed
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. Sci Rep. 2020 05 29; 10(1):8766.
View in:
PubMed
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020 12; 38(6):1784-1795.
View in:
PubMed
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020 05 15; 22(5):601-612.
View in:
PubMed
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in:
PubMed
Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Sci Rep. 2020 03 20; 10(1):5095.
View in:
PubMed
Deep-Learning Detection of Cancer Metastases to the Brain on MRI. J Magn Reson Imaging. 2020 10; 52(4):1227-1236.
View in:
PubMed
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
View in:
PubMed
Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol. 2020 03 05; 22(3):369-380.
View in:
PubMed
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 04 01; 26(7):1586-1594.
View in:
PubMed
Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2020 Feb 01; 26(3):758.
View in:
PubMed
An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning. Neurosurgery. 2020 02 01; 86(2):E184-E192.
View in:
PubMed
Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. 2019 Oct 25; 1-11.
View in:
PubMed
Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov; 80:101896.
View in:
PubMed
Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
View in:
PubMed
Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019 Sep; 22(9):1533.
View in:
PubMed
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
View in:
PubMed
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
View in:
PubMed
Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. Theranostics. 2019; 9(21):6284-6299.
View in:
PubMed
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
View in:
PubMed
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 10 01; 25(19):5799-5807.
View in:
PubMed
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 2019 08; 84(2):327-336.
View in:
PubMed
Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019 Jun; 143(2):359-367.
View in:
PubMed
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019 05; 22(5):729-740.
View in:
PubMed
Efficacy and safety of immune checkpoint blockade for brain metastases. CNS Oncol. 2019 06; 8(2):CNS33.
View in:
PubMed
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486.
View in:
PubMed
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in:
PubMed
The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res. 2019 04 15; 25(8):2656-2663.
View in:
PubMed
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 01 01; 21(1):26-36.
View in:
PubMed
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 01 01; 21(1):106-114.
View in:
PubMed
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in:
PubMed
Pseudoprogression: fact or wishful thinking in neuro-oncology? Lancet Oncol. 2018 12; 19(12):1561-1563.
View in:
PubMed
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
View in:
PubMed
Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 12; 211(6):1342-1347.
View in:
PubMed
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2019 01 01; 25(1):290-299.
View in:
PubMed
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418.
View in:
PubMed
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
View in:
PubMed
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730.
View in:
PubMed
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
View in:
PubMed
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 08 02; 20(9):1262-1271.
View in:
PubMed
Immunotherapy for glioblastoma: going viral. Nat Med. 2018 08; 24(8):1094-1096.
View in:
PubMed
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. Eur J Cancer. 2018 09; 101:95-104.
View in:
PubMed
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045.
View in:
PubMed
Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell. 2018 07 09; 34(1):163-177.e7.
View in:
PubMed
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018 07 05; 20(8):1101-1112.
View in:
PubMed
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
View in:
PubMed
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 06 18; 20(7):897-906.
View in:
PubMed
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018 05 18; 20(6):838-847.
View in:
PubMed
Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. 2018 Oct; 14(24):2507-2520.
View in:
PubMed
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686.
View in:
PubMed
Concepts for Immunotherapies in Gliomas. Semin Neurol. 2018 02; 38(1):62-72.
View in:
PubMed
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2574-2584.
View in:
PubMed
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? J Neurooncol. 2018 May; 138(1):163-171.
View in:
PubMed
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
View in:
PubMed
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267.
View in:
PubMed
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
View in:
PubMed
Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep. 2018 01 09; 8(1):208.
View in:
PubMed
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. J Neurooncol. 2018 Apr; 137(2):349-356.
View in:
PubMed
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
View in:
PubMed
High-grade Gliomas. Continuum (Minneap Minn). 2017 Dec; 23(6, Neuro-oncology):1548-1563.
View in:
PubMed
Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
View in:
PubMed
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist. 2018 02; 23(2):157-e21.
View in:
PubMed
Immunotherapy for glioblastoma: on the sidelines or in the game? Discov Med. 2017 11; 24(133):201-208.
View in:
PubMed
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017 Dec; 80(6):1209-1217.
View in:
PubMed
Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
View in:
PubMed
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017 Aug 01; 19(8):1119-1126.
View in:
PubMed
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017 Nov; 14(11):695-707.
View in:
PubMed
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):965-975.
View in:
PubMed
Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369.
View in:
PubMed
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun; 13(6):363-374.
View in:
PubMed
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017 06; 22(6):709-718.
View in:
PubMed
Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515.
View in:
PubMed
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635.
View in:
PubMed
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in:
PubMed
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017 02; 39(2):225-239.
View in:
PubMed
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65.
View in:
PubMed
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology. 2017 Feb; 59(2):135-145.
View in:
PubMed
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576.
View in:
PubMed
The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. J Mol Diagn. 2016 11; 18(6):864-871.
View in:
PubMed
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
View in:
PubMed
Adult brainstem gliomas. Cancer. 2016 09 15; 122(18):2799-809.
View in:
PubMed
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in:
PubMed
Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 09 01; 34(25):3107-8.
View in:
PubMed
Checkpoint inhibition in meningiomas. Immunotherapy. 2016 06; 8(6):721-31.
View in:
PubMed
Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
View in:
PubMed
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-225.
View in:
PubMed
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
View in:
PubMed
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in:
PubMed
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016 Mar 01; 34(7):731-9.
View in:
PubMed
Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70.
View in:
PubMed
Rare glial tumors. Handb Clin Neurol. 2016; 134:399-415.
View in:
PubMed
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7.
View in:
PubMed
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in:
PubMed
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
View in:
PubMed
Dedication: Andrew T. Parsa. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii2.
View in:
PubMed
Introduction. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii1.
View in:
PubMed
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii32-vii40.
View in:
PubMed
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol. 2015 Nov; 16(11):54.
View in:
PubMed
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
View in:
PubMed
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 2015 Oct 20; 6(32):34030-7.
View in:
PubMed
Adult Atypical Teratoid/Rhabdoid Tumors. World Neurosurg. 2016 Jan; 85:197-204.
View in:
PubMed
Glioblastoma in the elderly: making sense of the evidence. Neurooncol Pract. 2016 Jun; 3(2):77-86.
View in:
PubMed
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in:
PubMed
Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
View in:
PubMed
Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep; 11(9):504-14.
View in:
PubMed
Brachytherapy in the treatment of recurrent aggressive falcine meningiomas. J Neurooncol. 2015 Sep; 124(3):515-22.
View in:
PubMed
Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in:
PubMed
107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 2015 Aug; 62 Suppl 1:198-9.
View in:
PubMed
Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy. 2015; 7(6):603-6.
View in:
PubMed
Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
View in:
PubMed
One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
View in:
PubMed
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. Oncologist. 2015 Jul; 20(7):727-8.
View in:
PubMed
Multicentric Low-Grade Gliomas. World Neurosurg. 2015 Oct; 84(4):1045-50.
View in:
PubMed
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 2015 Aug; 17(8):1043-5.
View in:
PubMed
A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):671-8.
View in:
PubMed
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
View in:
PubMed
How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
View in:
PubMed
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19; 519(7543):366-9.
View in:
PubMed
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015 May; 17(5):708-17.
View in:
PubMed
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
View in:
PubMed
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in:
PubMed
Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):764-5.
View in:
PubMed
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46.
View in:
PubMed
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
View in:
PubMed
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
View in:
PubMed
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in:
PubMed
Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70.
View in:
PubMed
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in:
PubMed
The future of antiangiogenic treatment in glioblastoma. Curr Opin Neurol. 2014 Dec; 27(6):675-82.
View in:
PubMed
Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9.
View in:
PubMed
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53.
View in:
PubMed
Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
View in:
PubMed
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
View in:
PubMed
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13.
View in:
PubMed
Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii24-35.
View in:
PubMed
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
View in:
PubMed
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in:
PubMed
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007.
View in:
PubMed
Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
View in:
PubMed
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015 Mar; 17(3):430-9.
View in:
PubMed
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep; 15(10):1100-8.
View in:
PubMed
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. J Neurosurg. 2014 Sep; 121(3):536-42.
View in:
PubMed
Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
View in:
PubMed
Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
View in:
PubMed
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
View in:
PubMed
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
View in:
PubMed
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
View in:
PubMed
Update on the use of angiogenesis inhibitors in adult patients with brain tumors. Clin Adv Hematol Oncol. 2014 May; 12(5):293-303.
View in:
PubMed
Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4.
View in:
PubMed
Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging. 2014; 9:357-67.
View in:
PubMed
Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. J Radiosurg SBRT. 2014; 3(1):37-42.
View in:
PubMed
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May; 16(5):696-706.
View in:
PubMed
Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210.
View in:
PubMed
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in:
PubMed
Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
View in:
PubMed
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol. 2013 Jun 20; 31(18_suppl):LBA2009.
View in:
PubMed
Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
View in:
PubMed
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in:
PubMed
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol. 2013 Aug; 114(1):135-40.
View in:
PubMed
Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
View in:
PubMed
Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
View in:
PubMed
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013; 18(3):273-80.
View in:
PubMed
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7.
View in:
PubMed
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8.
View in:
PubMed
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013 Apr; 2(2):185-95.
View in:
PubMed
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013.
View in:
PubMed
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol. 2013 Jan; 111(2):97-102.
View in:
PubMed
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012 Oct 23; 107(9):1481-7.
View in:
PubMed
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012 Nov; 110(2):245-50.
View in:
PubMed
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61.
View in:
PubMed
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
View in:
PubMed
Treatment of elderly patients with glioblastoma. Lancet Oncol. 2012 Jul; 13(7):656-7.
View in:
PubMed
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
View in:
PubMed
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1):63-70.
View in:
PubMed
A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35.
View in:
PubMed
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71.
View in:
PubMed
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol. 2012 Jul; 108(3):499-506.
View in:
PubMed
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18.
View in:
PubMed
A pilot study of IL-2Ra blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One. 2012; 7(2):e31046.
View in:
PubMed
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 01; 118(19):4759-67.
View in:
PubMed
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011 Dec; 2(12):1159-65.
View in:
PubMed
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
View in:
PubMed
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012 Mar; 107(1):213-21.
View in:
PubMed
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol. 2012 Mar; 107(1):155-64.
View in:
PubMed
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7.
View in:
PubMed
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
View in:
PubMed
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011 Oct 01; 29(28):e739-42.
View in:
PubMed
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011 Sep; 69(3):668-76.
View in:
PubMed
Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert Opin Pharmacother. 2011 Oct; 12(14):2265-9.
View in:
PubMed
Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012 Mar 01; 118(5):1302-12.
View in:
PubMed
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
View in:
PubMed
Monoclonal antibody blockade of IL-2 receptor a during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011 Sep 15; 118(11):3003-12.
View in:
PubMed
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011 Dec; 105(3):621-7.
View in:
PubMed
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol. 2011 Dec; 105(3):601-6.
View in:
PubMed
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. 2011 Jul 20; 29(21):2918-23.
View in:
PubMed
Advances in malignant glioma drug discovery. Expert Opin Drug Discov. 2011 Jul; 6(7):739-53.
View in:
PubMed
A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). J Clin Oncol. 2011 May 20; 29(15_suppl):2070.
View in:
PubMed
Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J Clin Oncol. 2011 May 20; 29(15_suppl):2030.
View in:
PubMed
Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2056.
View in:
PubMed
Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2055.
View in:
PubMed
Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. J Clin Oncol. 2011 May 20; 29(15_suppl):9090.
View in:
PubMed
Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2082.
View in:
PubMed
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
View in:
PubMed
Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2098.
View in:
PubMed
Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039.
View in:
PubMed
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2010.
View in:
PubMed
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011 Dec 01; 117(23):5351-8.
View in:
PubMed
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011 Jun 15; 17(12):4119-24.
View in:
PubMed
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):2018-24.
View in:
PubMed
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93.
View in:
PubMed
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011 Apr; 9(4):414-27.
View in:
PubMed
Knee deep in the nerve. Surv Ophthalmol. 2011 Jul-Aug; 56(4):362-70.
View in:
PubMed
Cilengitide: an RGD pentapeptide a?ß3 and a?ß5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011 Mar; 7(3):339-54.
View in:
PubMed
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.
View in:
PubMed
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46.
View in:
PubMed
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep. 2011 Feb; 13(1):42-9.
View in:
PubMed
A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One. 2011 Jan 26; 6(1):e16031.
View in:
PubMed
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.
View in:
PubMed
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):58-66.
View in:
PubMed
Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. Br J Radiol. 2011 Apr; 84(1000):327-33.
View in:
PubMed
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9.
View in:
PubMed
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011 Jun; 103(2):371-9.
View in:
PubMed
Treatment recommendations for primary extradural meningiomas. Cancer. 2011 Jan 01; 117(1):24-38.
View in:
PubMed
Targeting integrins in malignant glioma. Target Oncol. 2010 Sep; 5(3):175-81.
View in:
PubMed
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec; 12(12):1300-10.
View in:
PubMed
Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010 Aug; 113(2):301-9.
View in:
PubMed
Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol. 2010 Sep; 11(9):809-11.
View in:
PubMed
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010 Oct; 12(10):1061-70.
View in:
PubMed
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77.
View in:
PubMed
Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol. 2011 Jan; 101(1):155-9.
View in:
PubMed
Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. Oncologist. 2010; 15(6):636-47.
View in:
PubMed
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol. 2011 Jan; 101(1):57-66.
View in:
PubMed
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.
View in:
PubMed
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr; 11(4):373-82.
View in:
PubMed
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer. 2010 Feb 01; 116(3):695-704.
View in:
PubMed
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009 Dec 15; 101(12):1986-94.
View in:
PubMed
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009 Dec 15; 101(12):1995-2004.
View in:
PubMed
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9.
View in:
PubMed
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 01; 115(15):3501-11.
View in:
PubMed
Current available therapies and future directions in the treatment of malignant gliomas. Biologics. 2009; 3:15-25.
View in:
PubMed
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009 Jul 01; 115(13):2964-70.
View in:
PubMed
Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med. 2009 Jul; 15(7):726; author reply 727.
View in:
PubMed
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010 Jan; 96(2):219-30.
View in:
PubMed
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol. 2009 Dec; 95(3):393-400.
View in:
PubMed
Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):e13016.
View in:
PubMed
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2015.
View in:
PubMed
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2034.
View in:
PubMed
Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):e13025.
View in:
PubMed
Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2045.
View in:
PubMed
A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13024.
View in:
PubMed
Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13007.
View in:
PubMed
Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2040.
View in:
PubMed
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13002.
View in:
PubMed
Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol. 2009 May 20; 27(15_suppl):2046.
View in:
PubMed
Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol. 2009 May 20; 27(15_suppl):e13004.
View in:
PubMed
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2021.
View in:
PubMed
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009 May 15; 115(10):2188-98.
View in:
PubMed
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009 Oct; 95(1):129-134.
View in:
PubMed
Cancer: The nuances of therapy. Nature. 2009 Mar 19; 458(7236):290-2.
View in:
PubMed
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct; 11(5):556-61.
View in:
PubMed
Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009 Mar; 18(3):277-92.
View in:
PubMed
IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8):765-73.
View in:
PubMed
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009 Aug; 94(1):79-85.
View in:
PubMed
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10; 27(8):1262-7.
View in:
PubMed
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 01; 15(3):1064-8.
View in:
PubMed
Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage. 2009 Aug; 47 Suppl 2:T143-51.
View in:
PubMed
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7.
View in:
PubMed
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 01; 14(21):7068-73.
View in:
PubMed
Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009 Feb; 11(1):80-91.
View in:
PubMed
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct; 10(5):745-51.
View in:
PubMed
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008 Aug; 17(8):1225-35.
View in:
PubMed
Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051.
View in:
PubMed
Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2074.
View in:
PubMed
Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2084.
View in:
PubMed
Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2042.
View in:
PubMed
Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea. J Clin Oncol. 2008 May 20; 26(15_suppl):2071.
View in:
PubMed
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2011.
View in:
PubMed
Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):13008.
View in:
PubMed
Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. J Clin Oncol. 2008 May 20; 26(15_suppl):2026.
View in:
PubMed
Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). J Clin Oncol. 2008 May 20; 26(15_suppl):2057.
View in:
PubMed
Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol. 2008 May 20; 26(15_suppl):2021.
View in:
PubMed
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May; 8(5):717-32.
View in:
PubMed
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun; 10(3):320-9.
View in:
PubMed
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
View in:
PubMed
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun; 10(3):330-40.
View in:
PubMed
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr; 10(2):182-9.
View in:
PubMed
The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb; 9(1):1-22.
View in:
PubMed
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan; 49(1):30-8.
View in:
PubMed
Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol. 2008 Feb; 10(1):93-7.
View in:
PubMed
Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov; 25(4):1111-39, x.
View in:
PubMed
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20; 25(30):4722-9.
View in:
PubMed
Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 01; 110(1):13-24.
View in:
PubMed
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct; 34(7):779-85.
View in:
PubMed
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007 May; 7(5):675-87.
View in:
PubMed
A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage. 2007; 37 Suppl 1:S116-9.
View in:
PubMed
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 2007 Jul; 9(3):343-53.
View in:
PubMed
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May; 34(4):405-13.
View in:
PubMed
Neurofibromatosis type 2. Neurology. 2007 Mar 27; 68(13):E14.
View in:
PubMed
Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr; 9(2):161-8.
View in:
PubMed
Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. Psychooncology. 2007 Mar; 16(3):232-40.
View in:
PubMed
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol. 2007 Mar; 188(3):703-9.
View in:
PubMed
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15; 13(4):1253-9.
View in:
PubMed
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May; 83(1):53-60.
View in:
PubMed
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):70-4.
View in:
PubMed
3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006 Nov-Dec; 8(6):340-7.
View in:
PubMed
Exercise interest and preferences among patients diagnosed with primary brain cancer. Support Care Cancer. 2007 Jan; 15(1):47-55.
View in:
PubMed
An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1560.
View in:
PubMed
Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11522.
View in:
PubMed
Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1573.
View in:
PubMed
A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1580.
View in:
PubMed
Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1568.
View in:
PubMed
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1506.
View in:
PubMed
Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11504.
View in:
PubMed
Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1539.
View in:
PubMed
Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2529.
View in:
PubMed
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun; 47(6):912-8.
View in:
PubMed
Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer. 2006 May 15; 106(10):2224-32.
View in:
PubMed
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1970-82.
View in:
PubMed
Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006 Apr; 77(2):207-12.
View in:
PubMed
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1253-65.
View in:
PubMed
Glioblastoma--more questions than answers? Nat Clin Pract Oncol. 2006 Feb; 3(2):60-1.
View in:
PubMed
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64.
View in:
PubMed
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):860-8.
View in:
PubMed
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 01; 24(1):115-22.
View in:
PubMed
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20; 23(36):9359-68.
View in:
PubMed
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005 Nov 15; 11(22):8145-57.
View in:
PubMed
Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005 Oct 15; 104(8):1693-9.
View in:
PubMed
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 01; 104(7):1478-86.
View in:
PubMed
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87.
View in:
PubMed
Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005 Sep 01; 10:2645-68.
View in:
PubMed
A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1565.
View in:
PubMed
Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. J Clin Oncol. 2005 Jun; 23(16_suppl):1515.
View in:
PubMed
Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):1510.
View in:
PubMed
A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. J Clin Oncol. 2005 Jun; 23(16_suppl):3063.
View in:
PubMed
A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1540.
View in:
PubMed
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005 Jun; 46(6):1042-51.
View in:
PubMed
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15; 103(2):329-38.
View in:
PubMed
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol. 2005 Jan; 7(1):90-6.
View in:
PubMed
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12.
View in:
PubMed
Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther. 2004 Sep; 4(9):1453-71.
View in:
PubMed
Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1569.
View in:
PubMed
Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1554.
View in:
PubMed
A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1512.
View in:
PubMed
A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9682.
View in:
PubMed
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1513.
View in:
PubMed
Kluver-Bucy syndrome related to glioma. Neurology. 2004 Jul 13; 63(1):184.
View in:
PubMed
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr; 6(2):145-53.
View in:
PubMed
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr; 6(2):134-44.
View in:
PubMed
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 01; 22(1):133-42.
View in:
PubMed
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct; 65(1):27-35.
View in:
PubMed
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 01; 21(11):2187-91.
View in:
PubMed
Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):9-14.
View in:
PubMed
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003 Apr 15; 97(8):1963-8.
View in:
PubMed
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15; 21(4):646-51.
View in:
PubMed
Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 01; 20(13):2951-8.
View in:
PubMed
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
View in:
PubMed
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 01; 20(5):1389-97.
View in:
PubMed
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer. 2001 Jun 15; 84(12):1591-8.
View in:
PubMed
The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001 Mar 15; 20(11):1388-97.
View in:
PubMed
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant. 2001; 7(5):284-93.
View in:
PubMed
Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90.
View in:
PubMed
Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):247-51.
View in:
PubMed
Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg. 2000 Apr; 32(4):187-91.
View in:
PubMed
Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999 Dec; 17(12):3720-8.
View in:
PubMed
Malignant evolution of choroid plexus papilloma. Pediatr Neurosurg. 1999 Sep; 31(3):127-30.
View in:
PubMed
Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol. 1999 Jun; 17(6):1825-8.
View in:
PubMed
Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):249-54.
View in:
PubMed
Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999 Mar; 24(3):230-7.
View in:
PubMed
High-grade pediatric spinal cord tumors. Pediatr Neurosurg. 1999 Jan; 30(1):1-5.
View in:
PubMed
Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg. 1998 Jul; 29(1):29-35.
View in:
PubMed
Chromosomal localization of the human smoothened gene (SMOH) to 7q32. 3 by fluorescence in situ hybridization and radiation hybrid mapping. Genomics. 1998 May 15; 50(1):112-4.
View in:
PubMed
MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar; 16(3):897-906.
View in:
PubMed
Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997 Sep 15; 57(18):4042-7.
View in:
PubMed
Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein. J Interferon Cytokine Res. 1995 Jan; 15(1):55-61.
View in:
PubMed
Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 1994 Mar 01; 73(5):1526-32.
View in:
PubMed
The microfocus assay system (mfas) - a simple quantitative assay to identify inhibitory drugs targeted against specific oncogenes. Oncol Rep. 1994 Jan; 1(1):37-41.
View in:
PubMed
Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood. 1992 Jul 15; 80(2):551-5.
View in:
PubMed
Differential impact of abortion on adolescents and adults. Adolescence. 1992; 27(105):161-72.
View in:
PubMed
Virus-associated hemophagocytic syndrome following bone marrow transplantation. Am J Pediatr Hematol Oncol. 1991; 13(3):305-9.
View in:
PubMed
The size and number of bone marrow megakaryocytes in malignant lymphoma and their relationship to abnormalities in platelet count. Am J Hematol. 1990 Dec; 35(4):225-31.
View in:
PubMed